Intuitive Surgical, Inc. $ISRG Shares Sold by Diversified Trust Co

Key Points

• Diversified Trust Co has reduced its stake in Intuitive Surgical, Inc. by 42.7%, holding 3,094 shares valued at $1,681,000 after selling 2,307 shares in the second quarter.
• A significant 54,010.7% increase in holdings was reported by GAMMA Investing LLC, now owning over $14.9 billion worth of Intuitive Surgical stock.
• Wall Street analysts generally maintain a positive outlook with an average rating of "Moderate Buy" and a target price of approximately $595.95 on Intuitive Surgical shares.

Diversified Trust Co decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 42.7% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,094 shares of the medical equipment provider's stock after selling 2,307 shares during the period. Diversified Trust Co's holdings in Intuitive Surgical were worth $1,681,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Nuveen LLC purchased a new stake in shares of Intuitive Surgical in the first quarter valued at approximately $1,715,899,000. GAMMA Investing LLC increased its holdings in Intuitive Surgical by 54,010.7% in the 1st quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider's stock worth $14,999,630,000 after acquiring an additional 3,022,979 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Intuitive Surgical by 26.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,819,666 shares of the medical equipment provider's stock worth $1,396,496,000 after acquiring an additional 584,375 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Intuitive Surgical by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,393,951 shares of the medical equipment provider's stock worth $1,680,922,000 after acquiring an additional 566,979 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in Intuitive Surgical by 15.0% during the first quarter. Wellington Management Group LLP now owns 3,499,052 shares of the medical equipment provider's stock valued at $1,732,975,000 after purchasing an additional 457,080 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ISRG has been the subject of a number of research reports. Piper Sandler reissued an "overweight" rating and set a $595.00 target price (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. Erste Group Bank reissued a "hold" rating on shares of Intuitive Surgical in a report on Wednesday, July 23rd. BTIG Research lifted their price target on Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Finally, Wall Street Zen upgraded Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Thirteen equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Intuitive Surgical presently has an average rating of "Moderate Buy" and an average target price of $595.95.

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $438.72 on Monday. The business has a 50-day moving average of $476.64 and a two-hundred day moving average of $503.43. The company has a market capitalization of $157.27 billion, a price-to-earnings ratio of 61.19, a price-to-earnings-growth ratio of 4.60 and a beta of 1.61. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business's revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.78 EPS. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Amy L. Ladd sold 335 shares of the business's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $440.69, for a total value of $147,631.15. Following the completion of the sale, the director directly owned 739 shares of the company's stock, valued at $325,669.91. The trade was a 31.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary S. Guthart sold 29,360 shares of the firm's stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $472.49, for a total value of $13,872,306.40. Following the transaction, the insider directly owned 19,827 shares in the company, valued at approximately $9,368,059.23. The trade was a 59.69% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 45,224 shares of company stock valued at $21,716,492. 0.70% of the stock is owned by corporate insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.